ArticleRSC advances2026
Haematological and biochemical profiling combined with HRAMS-based metabolomics reveals the potential biomarkers of
Article in RSC advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lymphatic filariasis (LF) encompasses grotesque and irreversible chronic conditions such as lymphedema, hydrocele, and elephantiasis. Asymptomatic or subclinical infections remain largely unnoticed as microscopy, serological tests, and antigen detection typically lack sufficient sensitivity to detect circulating microfilariae. Herein, we utilised high-resolution accurate mass spectrometry (HRAMS)-based metabolomics to thoroughly examine host metabolic responses in 25 patients with active microfilaremic infections compared with 30 healthy controls. Metabolites were annotated using the Compound Discoverer platform and analysed with MetaboAnalyst, confirming significant differential levels of 161 metabolites. The PCA scoring plot showed clear segregation between the two groups (R2X = 0.892 for the positive ESI mode and R2X = 0.904 for the negative ESI mode). The VIP score plots confirmed the top 15 defining metabolites (scores > 1.3), with arachidoyl ethanolamide, retinal, 17-OH pregnenolone sulfate, and
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.